Monitor for IND submission in 2027 and any future clinical trial initiation; near-term upside is limited to sentiment shifts from preclinical enthusiasm, but high biotech risk remains due to early stage and lack of human data.
Price Chart
Executive Summary
Xilio Therapeutics released preclinical data for XTX601, a masked T cell engager targeting CLDN18.2, demonstrating tumor-selective activation, potent anti-tumor activity, and favorable tolerability in non-human primates. The data support advancement into IND-enabling studies with an IND submission planned for 2027. While promising, these are early-stage results with no clinical efficacy yet demonstrated.
Key Facts
- XTX601 is a first-in-class masked T cell engager targeting CLDN18.2, expressed in gastric, pancreatic, and esophageal cancers.
- Preclinical data show protease-dependent activation, robust anti-tumor activity in xenograft models, and no cytokine release syndrome or liver enzyme changes in non-human primates.
- Xilio plans to submit an IND for XTX601 in 2027, meaning clinical trials are still over a year away.
- No human data or financial metrics (revenue, EPS) are available; results are preclinical only.
Financial Impact
No immediate financial impact; potential long-term value if clinical development succeeds
Risk Factors
- Preclinical results may not translate to humans
- Development timelines could be delayed
- High dilution risk as company will likely need to raise capital before clinical stages
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276473 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.16 (−9.81%) |
Aug 12, 2026 10w ago | Press Release | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.16 (−9.81%) |
Jun 1, 2026 21w ago | EFFECT | $8.25 $7.70 | ▲ +6.67% | ▲ +3.92% | $8.16 (+1.06%) |
May 27, 2026 21w ago | S-3/A | $8.52 $8.15 | ▼ −4.40% | ▼ −4.35% | $8.16 (−4.20%) |
May 12, 2026 23w ago | 8-K | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.16 (+5.60%) |
May 12, 2026 23w ago | Press Release | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.16 (+5.60%) |
Apr 17, 2026 27w ago | Press Release | $8.45 $8.18 | ▼ −3.20% | ▼ −4.11% | $8.16 (−3.40%) |
Apr 16, 2026 27w ago | 3 | $8.57 $8.31 | ▼ −3.03% | ▼ −3.59% | $8.16 (−4.75%) |
Apr 16, 2026 27w ago | 8-K | $8.35 $8.47 | ▲ +1.44% | ▲ +0.45% | $8.16 (−2.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers